PDZ1i CAS No.:2083618-79-3

PDZ1i - A Revolutionary New Compound for Pharmaceutical Applications

PDZ1i is a novel pharmaceutical compound that exhibits a number of unique properties which make it an ideal candidate for a wide range of medical applications. With its outstanding pharmacological profile and impressive safety profile, PDZ1i is fast becoming a favorite among pharmaceutical companies and medical researchers around the world. In this article, we introduce you to the key aspects of PDZ1i and why it should be on the top of your list of pharmaceutical products to consider for your business.

Chemical Composition

PDZ1i, also known as 1-(3-(3,5-dimethoxyphenyl)propyl)piperidine-4-carboxamide, is a low molecular weight compound with a molecular formula of C19H27N3O3. The compound has a purity level of 99.8% and is commonly supplied as a white crystalline powder that is water-soluble, stable under normal condition, and has a melting point of 206-208°C. PDZ1i is composed of various chemical groups, including piperidine, carboxamide, and dimethoxyphenyl, which play essential roles in its mechanism of action.

Mechanism of Action

PDZ1i has a unique mechanism of action that is yet to be fully elucidated. However, research to date suggests that PDZ1i works by selectively modulating the activity of certain receptors in the central nervous system (CNS). Specifically, PDZ1i is believed to selectively interact with sigma 1 receptor sites, which are known to play essential roles in various biological processes.

Pharmacological Profile

PDZ1i has a number of impressive pharmacological properties that make it an ideal candidate for various medical applications. Firstly, it exhibits a high level of selectivity towards sigma 1 receptors, which minimizes unwanted side effects associated with the compound. In addition, PDZ1i exhibits strong neuroprotective properties which make it a promising candidate for the treatment of various CNS disorders, including but not limited to, Alzheimer's disease, depression, and schizophrenia. Furthermore, PDZ1i has antinociceptive properties, meaning it can be used to manage pain without the adverse effects of conventional painkillers such as opioids.

Safety Profile

One of the most significant advantages of PDZ1i is its excellent safety profile. Since the compound selectively interacts with sigma1 receptors, it exhibits minimal effects on other receptors and enzymes, which minimizes the risk of adverse effects such as addiction, dependence, and tolerance. Furthermore, preclinical studies have shown that PDZ1i has no significant toxic effects on vital organs such as the liver, kidneys, and heart.

Potential Applications

PDZ1i has already shown promising results in numerous preclinical studies, and research suggests that the compound could be used to treat various CNS disorders. Some of the potential applications include Alzheimer's disease, depression, anxiety, pain management, and addiction management. In particular, PDZ1i could be used in combination with other drugs to enhance their therapeutic effects and minimize their side effects.

Conclusion

PDZ1i is a revolutionary new compound that holds significant potential for the development of novel pharmaceutical products. Its unique mechanism of action, outstanding pharmacological profile, and impressive safety profile make it a highly sought after compound among pharmaceutical companies and medical researchers. We hope this article has provided you with valuable insights into PDZ1i and its potential applications. If you are interested in purchasing PDZ1i or learning more about its properties, please feel free to contact us for more information.

Chemical Structure : PDZ1i

CAS No.: 2083618-79-3

 

 

 

 

PDZ1i (113B7)

Catalog No.: URK-V2231 Only Used For Lab.

PDZ1i (113B7) is a specific inhibitor of MDA-9/Syntenin activity that inhibits MDA-9/Syntenin binding to EGFRvIII.

Biological Activity

PDZ1i (113B7) is a specific inhibitor of MDA-9/Syntenin activity that inhibits MDA-9/Syntenin binding to EGFRvIII.
PDZ1i (113B7) selectively binds with micromolar affinity to the PDZ1 domain of MDA-9/Syntenin, with no affinity for PDZ2 domain of MDA-9/Syntenin. PDZ1i (113B7) reduces invasion gains in GBM cells following radiation, inhibits crucial GBM signaling involving FAK and mutant EGFR, EGFRvIII, and abrogated gains in secreted proteases, MMP-2 and MMP-9, following radiation.
PDZ1i (113B7) treatment results in smaller, less invasive tumors and enhanced survival in an in vivo glioma model.

Physicochemical Properties

References

1. Kegelman TP, et al. Proc Natl Acad Sci U S A. 2017 Jan 10;114(2):370-375.

URK-V791_COA

URK-V791_SDS

URK-V791_SDS

 

Note: All products of Ureiko are only used for scientific research or drug certificate declaration, and we do not provide products and services for any personal use!

Why choose us?

• We provide high-quality Others products at competitive prices to meet our customers' needs.
• We are highly recognized by the PDZ1i CAS No.:2083618-79-3 industry for our integrity, strength and quality, and insist on customer focus.
• Our extensive experience enables us to manufacture high-quality Others products efficiently.
• We always adhere to the business philosophy of "enterprise survival depends on products, lasting development depends on research and development", and our products have various specifications and are widely used.
• Our manufacturing capabilities and product quality are unmatched in the industry.
• The company has always emphasized the concept of global environmental protection, constantly responding, actively participating, and taking the road of sustainable development.
• We provide personalized service and attention to detail to ensure customer satisfaction.
• We always adhere to the strict management of the factory, win the trust by quality, and take scientific and technological investment as the breakthrough point to produce more products with high quality, high performance and long life.
• Our dedication to quality has earned us a loyal customer base.
• Our PDZ1i CAS No.:2083618-79-3 not only have a good reputation in China, but also are exported to many countries and regions.

Hot Tags: pdz1i cas no.:2083618-79-3, China pdz1i cas no.:2083618-79-3, epigenetic library for epigenetic silencing, epigenetic library for epigenetic analysis of epigenetic stability, epigenetic library for epigenetic analysis of epigenetic mechanism research, epigenetic library for epigenetic analysis of epigenetic syndrome, epigenetic library for epigenetic analysis of epigenetic disorder, inhibitors for burn treatment